Wednesday, 16 Oct 2019

You are here

Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis

Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments. The role of TGF-β in SSc, was put to the test in a trial of 15 SSc patients (with a mean disease duration of 8 months) who were treated with 2 different dosing regimens of fresolimumab (an IgG4 κ monoclonal antibody capable of neutralizing TGF-β).  

Patients received either two doses of 1 mg/kg 4 weeks apart (n=7) or one 5 mg/kg dose (n=8) and were assessed at baseline, weeks 3 or 4, 7, and 24 weeks with modified Rodnan skin scores (mRSS), serial skin biopsies, biomarkers and microarrays.  Among the 11 females and 4 males, 60% had digital ulcers, 93% were ANA+, 27% were SCL-70 Ab positive and they had a mean mRSS of 26.9. Only one patient had pulmonary fibrosis.

Rice and coworkers reported that nearly all patients showed a rapid, significant decrease in skin scores, Expression of the biomarkers thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) rapidly declined at one month and week 7. Skin scores began to reverse after week 11 but COMP and THBS1 expression lagged behind, suggesting repeat dosing may be needed in the future.  

Nevertheless, strong correlations were seen between biopsy site (forearm) scores, mRSS, COMP and THBS1.  When compared to other trials, the degree and rapidity of mRSS improvement suggest these changes were more than the natural regression of skin scores in SSc. This this open-label pilot trial, using a first in class inhibitor of TGF-β, has shown significant clinical and biologic effects in patients with diffuse scleroderma.

Thanks to Dr. Barry Gruber of Long Island for identifying this citation.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.

ILD Patients At Risk for Autoimmune Disease

Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).

A retrospective study of interstitial lung disease (ILD) patients from the Columbia University Irving Medical Center (2009 to 2017) looked for those who did or did not meet IPAF criteria.

MMWR: Increased Opioid Use in Lupus

Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for preference and adverse health effects.